Curexo Reports Q1 2026 Consolidated Revenue of KRW 16.1B, Operating Loss of KRW 0.9B

Consolidated Q1 revenue KRW 16.1B (down 18.3% YoY), operating loss KRW 0.9B (vs profit KRW 0.8B in Q1 2025), net profit KRW 0.5B (vs KRW 1.1B)
By segment: Medical Robot revenue KRW 5.7B, operating loss KRW 1.4B; Implant revenue KRW 3.6B, operating profit KRW 0.3B; Trading revenue KRW 6.7B, operating profit KRW 0.1B
Debt ratio 6.07%, cash and cash equivalents KRW 16.9B, indicating sound financial structure
169,800 new shares issued via stock option exercise, capital stock increased to KRW 20.6B
R&D expenses KRW 2.1B (13.3% of revenue)
Additional investment of KRW 0.6B in Indian subsidiary Curexo India

ADVERTISEMENT (250px+)